Cushing's Syndrome clinical trials at UCSF

1 research study open to eligible people

(PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome
open to eligible people ages 2-17
Multicenter, open-label, non-comparative study to evaluate the pharmacokinetics, pharmacodynamics, and tolerability of osilodrostat in children and adolescent patients with Cushing's syndrome.
San Francisco, California and other locations

Last updated: March 2026